Depomed Inc (DEPO)

5.91
0.09 1.40
NASDAQ : Health Care
Prev Close 5.99
Open 5.95
Day Low/High 5.86 / 6.01
52 Wk Low/High 12.25 / 33.16
Volume 854.96K
Avg Volume 1.79M
Exchange NASDAQ
Shares Outstanding 62.99M
Market Cap 391.16M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week of October 20th Options Trading For Depomed (DEPO)

Investors in Depomed Inc saw new options become available this week, for the October 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DEPO options chain for the new October 20th contracts and identified one put and one call contract of particular interest.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Depomed, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Depomed, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Depomed, Inc.

Opioid Makers Buffeted by Trump's Declaration of Addiction Crisis

Opioid Makers Buffeted by Trump's Declaration of Addiction Crisis

The companies are subject to either state, federal or congressional inquiries into their marketing practices for prescription opioids, which are blamed for helping to fuel rising numbers or addicted individuals.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Depomed, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Depomed, Inc.

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Depomed, Inc.

Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study

Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study

FibroGen, Depomed and Valeant were among the biotech stock movers in premarket trading on Aug. 8.

Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Depomed, Inc. Investors

Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Depomed, Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Depomed, Inc.

Depomed Enters Oversold Territory (DEPO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Interesting DEPO Put And Call Options For March 2018

Interesting DEPO Put And Call Options For March 2018

Investors in Depomed Inc saw new options become available today, for the March 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Depomed Announces Intent To Effect A Debt Refinancing

Depomed Announces Intent To Effect A Debt Refinancing

Provides Selected Preliminary Second Quarter 2017 Financial Results and Reconfirms Full Year Financial Guidance

Interesting DEPO Put And Call Options For August 18th

Investors in Depomed Inc saw new options begin trading this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DEPO options chain for the new August 18th contracts and identified one put and one call contract of particular interest.

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

The FDA requested Endo to remove its opioid pain medication from the market, expressing concern that the "benefits of the drug may no longer outweigh its risks."

Young Guns of Activism Join Boards at AIG, SunOpta and DepoMed

Young Guns of Activism Join Boards at AIG, SunOpta and DepoMed

A review of data produced by BoardEx reveals that many big and small activist-targeted corporate boards feature young directors in their early-to-mid 30s who work for insurgent fund managers

Depomed Announces Corporate Governance Updates

Sets Date of 2017 Annual Meeting of Shareholders

Depomed Focuses on Flagship Drug Rather Than M&A: CEO

Depomed Focuses on Flagship Drug Rather Than M&A: CEO

The company's new CEO tells analysts it continues to believe the novel painkiller Nucynta can be a blockbuster.

Biotech Movers: Depomed Shares Tank After Losses Get Even Worse

Biotech Movers: Depomed Shares Tank After Losses Get Even Worse

Depomed unveiled steps the company is taking to shore itself up.

Analysts' Actions -- Allergan, Coach, General Dynamics, Occidental and More

Analysts' Actions -- Allergan, Coach, General Dynamics, Occidental and More

Here are Wednesday's top research calls, including downgrades for Allergan and General Dynamics, and upgrades for Coach and Occidental Petroleum.

Bearish Bets: A Furniture Retailer, a Logistics Firm and Other Stocks That Look Good Short

CYBE, TIS, HUBG, DEPO and ETH all recently were downgraded by TheStreet's Quant Ratings.